Erzofri on SilverScript Choice (S5601-038)
paliperidone palmitate
Covered.
Tier 4 (non-preferred drug). Quantity limit of 0.25 per 28 days.
$248.67
Patient pays / month, after deductible
$660.72
Patient pays / month, before the $615.00 deductible
$746.00
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap
ERZOFRI EXTENDED-RELEASE 39 mg/.25mL Injection at a preferred retail pharmacy, from the plan's negotiated price of $753.54 for a month. Other covered strengths are listed below.
All 6 covered strengths and forms
| Form | Tier | Patient pays / month | Limits |
|---|---|---|---|
| ERZOFRI EXTENDED-RELEASE 117 mg/.75mL Injection | 5 | $558.22 | 0.75 per 28 days |
| ERZOFRI EXTENDED-RELEASE 156 mg/mL Injection | 5 | $697.79 | 1 per 28 days |
| ERZOFRI EXTENDED-RELEASE 234 mg/1.5mL Injection | 5 | $1,395.55 | 1.5 per 28 days |
| ERZOFRI EXTENDED-RELEASE 351 mg/2.25mL Injection | 5 | $258.18 | 4.5 per 365 days |
| ERZOFRI EXTENDED-RELEASE 39 mg/.25mL Injection | 4 | $248.67 | 0.25 per 28 days |
| ERZOFRI EXTENDED-RELEASE 78 mg/.5mL Injection | 5 | $376.79 | 0.5 per 28 days |
Verify with the plan before prescribing or filling. Member services: (866)235-5660. Data from the CMS 2026 Part D formulary and pricing files. Full plan details
Plan ID s5601-038